Endogenous testosterone to prostate-specific antigen relationship in men without prostatic diseases: a 10-year retrospective study

Promise N. Wichendu, Ehimen P. Odum, Collins Amadi, Benjamin M. Aleme


Background: The relationship between endogenous testosterone and PSA in men without prostatic diseases is controversial. Hence, this study was designed to investigate this relationship among healthy Nigerian men.

Methods: A retrospective study of serum total testosterone (TT) and total PSA records of 1066 prostate disease-free men was undertaken in a Nigerian tertiary Hospital. Data on age, serum testosterone, and PSA from 1st January 2007 to December 2016 was abstracted and analysed.

Results: The mean age, serum PSA, and serum total testosterone levels among study cohorts are 58.40±12.24 years, 3.0±2.24 µg/l, and 15.5±0.53 nmol/l respectively. There was an inverse relationship between serum PSA and testosterone levels with age. Subjects with high-risk PSA level (PSA>4.0 µg/l) had statistically significant higher PSA (p<0.001) and TT (p<0.001) values compared to the low-risk PSA level group. Subjects in the eugonadism group had higher PSA levels than those in the hypogonadism group (eugonadism 3.90µg/l±2.22 versus hypogonadism 2.18µg/l±2.30; p=0.012). Age correlated positively with PSA (p<0.001), but negatively with TT (p<0.001) while PSA correlated positively with TT (p<0.001).

Conclusions: The findings of this study suggest an association between endogenous TT and PSA among healthy men without prostatic diseases and augment the evidence that serum TT maybe linked to prostate diseases. Clinical decisions regarding PSA should factor the levels of endogenous TT to enhance clinical judgments.


Age, Nigeria, PSA, Prostate-specific antigen, Testosterone

Full Text:



Armbrusta DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem. 1993;39(2);181-95.

Malm J, Lilja H. Biochemistry of prostate-specific antigen, PSA. Scand J Clin Lab Invest Suppl. 1995;221:15-22.

Walsh PC. Using prostate-specific antigen to diagnose prostate cancer:sailing in uncharted waters. Ann Intern Med. 1993;119:948-9.

Prcic A, Begic E, Hiros M. Usefulness of total PSA value in prostate diseases diagnosis. Acta Inform Med. 2016;24(3):156-61.

Collins GN, Lee RJ, Mckelvie GB, Rogers AC, Hemir M. Relationship between prostate-specific antigen, prostate volume and age in benign prostate. Br J Urol. 1993;71(4):445-50.

Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostate hyperplasia. Asian J Androl. 2015;17 (2):212-6.

Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer:from physiology to clinical implications. Euro Urol. 2014;65:115-23.

Wilson JD. Recent studies on the mechanism of action of testosterone. N Engl J Med. 1971;287;1284-91.

Hsing AW. Hormones and prostate cancer:What’s next? Epidemiol Rev. 2001;23(1):42-58.

Carson C 3rd, Rittmaster R. The role of dihydrotestosteerone in benign prostatic hyperplasia. Urology. 2003;6 (suppl 1):2-7.

Riegman PH, Vietstra RJ, Van der korput JA, Romijin JC, Trapman J. Characterization of the prostate-specific antigen gene:a novel kallikrein-like gene. Biochem Biophys Res Cmmun. 1989;159(1):95-102.

Schalken JA. Molecular and cellular biology:origin of prostate-specific antigen expression and implications of benign prostatic hyperplasia. BJU Int. 2004;93(1):5-9.

Peskoe SB, Joshua CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G, et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015;75 (11):1167-76.

Elzanaty S, Rezenezhad B, Dohle G. Association between serum testosterone and PSA levels in middle-aged healthy men from the general population. Curr Urol. 2017;10(91):40-4.

Mustafa M, Horuz R, Celik M, Kucukcan A. Is there an association between serum prostate-specific antigen values and serum testosterone levels in healthy men? Korean J Urol. 2014;55(7):465-9.

Koo JM, Shim BS. Significance of serum testosterone for prostate-specific antigen (PSA) elevation and prediction of prostate cancer in patients with PSA above 10ng/ml. Korean J Urol. 2010;51(12):831-5.

Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer:the saturation model and the limits of androgen-dependent growth. Euro Urol. 2009;55(2):310-21.

Cooper CS, Perry PJ, Sparkes ET, Maclndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate-specific antigen levels in healthy young men. J Urol. 1998;159(2):441-1.

Gerstenbult RE, Manian PN, Corty EW, Seftel AD. Prostate-specific changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23(6);922-6.

Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of gamma seminoprotein, an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi. 1971;25(4):322-4.

Wu FC, Tajar A, Pre SR, Silman AJ, Fin JD, O’Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors:European male aging study. J Clin Endocrinol Metab. 2008;93(7):2737-45.

Leifke E, Gorenoi V, Wichens C, Von Zur Muhlen A, Von Buren E, Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men:cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf). 2000;53 (6);689-95.

Isaac JT, Coffrey DS. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology. 1981;2:445-53.

Osterling JE. Using Prostate-specific Antigen to eliminate unnecessary diagnostic test: Significant worldwide economic implications. Urology. 1995;46(suppl 3A):26-33.

Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Beman N, et al. Testosterone dose-response relationship in healthy young men. Am J Physiol Eandocrinol Metab. 2001;281(6);E1172-81.